dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2016-01-28T16:56:40Z
dc.date.available2016-01-28T16:56:40Z
dc.date.created2016-01-28T16:56:40Z
dc.date.issued2012
dc.identifierInternational Research Journal of Pharmacy and Pharmacology, v. 2, n. 1, p. 001-009, 2012.
dc.identifier2251-0176
dc.identifierhttp://hdl.handle.net/11449/133803
dc.identifier5178218874772717
dc.identifier9734333607975413
dc.identifier5737933639516944
dc.identifier0000-0003-4141-0455
dc.description.abstractTuberculosis is a chronic infectious disease caused by etiologic agent Mycobacterium tuberculosis. "It has been reported that rates of incidence is increasing and each year around 8.9-9.9 million new cases are detected”. The current TB therapy presents several problems such as long-term therapy, drug resistance, no-compliance to therapy and few therapeutic sources to treat the disease. The discovery of new drugs safer and more efficient is urgent. The molecular modification is an important tool that allows discovering new compounds that can be win these challenges. In this work, we summarize the main strategies useful to obtain a new antitubercular drug.
dc.languageeng
dc.relationInternational Research Journal of Pharmacy and Pharmacology
dc.rightsAcesso restrito
dc.sourceCurrículo Lattes
dc.subjectTuberculosis
dc.subjectAntitubercular drugs
dc.subjectNew drugs
dc.subjectMolecular modification
dc.titleAntitubercular drug discovery: the molecular modification as promise tool
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución